Denali Therapeutics Inc.

Q2 2026 13F Holders

Symbol
DNLI
CUSIP
24823R105
Type
Equity
Class
COM
Num filings
305
Total reported value, excl. options
$4.61 B
Manager Report Date Value ($000) Shares Option Type